Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33769-33780

  Xiang, Wei ^a   Cheong, Jit Kong ^b   Ang, Shi Hui ^b   Teo, Bryan ^a   Xu, Peng ^b   Asari, Kartini ^a   Sun, Wen Tian ^b   Than, Hein ^a   Bunte, Ralph M ^b   Virshup, David M ^b,c   Chuah, Charles ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myeloid leukemia; Mitochondrial respiration; Pyrvinium

Indexed keywords

BETA CATENIN; CASEIN KINASE IALPHA; CD34 ANTIGEN; DASATINIB; PYRVINIUM EMBONATE; WNT PROTEIN; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASEIN KINASE I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEM CELL; TUMOR XENOGRAFT; UMBILICAL CORD BLOOD; ANIMAL; BLAST CELL CRISIS; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; IC50; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MITOCHONDRION; PHOSPHORYLATION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BETA CATENIN; BLAST CRISIS; CASEIN KINASE I; CELL LINE, TUMOR; CELL PROLIFERATION; DASATINIB; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, SCID; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PYRVINIUM COMPOUNDS; RNA INTERFERENCE;

EID: 84946078586     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5615     Document Type: Article

References (33)

1. R. Hehlmann. How I treat CML blast crisis. Blood. 2012; 120: 737-47.
2. D. Perrotti, C. Jamieson, J. Goldman and T. Skorski. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010; 120: 2254-64.
3. S. Lim, T. Y. Saw, M. Zhang, M. R. Janes, K. Nacro, J. Hill, A. Q. Lim, C. T. Chang, D. A. Fruman, D. A. Rizzieri, S. Y. Tan, H. Fan, C. T. Chuah, et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013; 110: E2298-307.
4. T. O'Hare, M. S. Zabriskie, A. M. Eiring and M. W. Deininger. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012; 12: 513-26.
5. M. Jaras and B. L. Ebert. Power cut: inhibiting mitochondrial translation to target leukemia. Cancer Cell. 2011; 20: 555-6.
6. E. D. Lagadinou, A. Sach, K. Callahan, R. M. Rossi, S. J. Neering, M. Minhajuddin, J. M. Ashton, S. Pei, V. Grose, K. M. O'Dwyer, J. L. Liesveld, P. S. Brookes, M. W. Becker, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12: 329-41.
7. M. Skrtic, S. Sriskanthadevan, B. Jhas, M. Gebbia, X. Wang, Z. Wang, R. Hurren, Y. Jitkova, M. Gronda, N. Maclean, C. K. Lai, Y. Eberhard, J. Bartoszko, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20: 674-88.
8. R. C. Jung. Treatment of intestinal parasitic disease. South Med J. 1976; 69: 799-804.
9. R. Lamb, B. Ozsvari, C. L. Lisanti, H. B. Tanowitz, A. Howell, U. E. Martinez-Outschoorn, F. Sotgia and M. P. Lisanti. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015; 6: 4569-84.
10. W. Xu, L. Lacerda, B. G. Debeb, R. L. Atkinson, T. N. Solley, L. Li, D. Orton, J. S. McMurray, B. I. Hang, E. Lee, A. H. Klopp, N. T. Ueno, J. M. Reuben, et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One. 2013; 8: e71508.
11. L. Deng, Y. Lei, R. Liu, J. Li, K. Yuan, Y. Li, Y. Chen, Y. Liu, Y. Lu, C. K. Edwards Iii, C. Huang and Y. Wei. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis. 2013; 4: e614.
12. Y. Harada, I. Ishii, K. Hatake and T. Kasahara. Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 2012; 319: 83-8.
13. D. H. Yu, J. Macdonald, G. Liu, A. S. Lee, M. Ly, T. Davis, N. Ke, D. Zhou, F. Wong-Staal and Q. X. Li. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One. 2008; 3: e3951.
14. I. Ishii, Y. Harada and T. Kasahara. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Front Oncol. 2012; 2: 137.
15. C. A. Thorne, A. J. Hanson, J. Schneider, E. Tahinci, D. Orton, C. S. Cselenyi, K. K. Jernigan, K. C. Meyers, B. I. Hang, A. G. Waterson, K. Kim, B. Melancon, V. P. Ghidu, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol. 2010; 6: 829-36.
16. B. Li, D. L. Fei, C. A. Flaveny, N. Dahmane, V. Baubet, Z. Wang, F. Bai, X. H. Pei, J. Rodriguez-Blanco, B. Hang, D. Orton, L. Han, B. Wang, et al. Pyrvinium attenuates Hedgehog signaling downstream of Smoothened. Cancer Res. 2014; 74:4811-21.
17. B. Li, C. A. Flaveny, C. Giambelli, D. L. Fei, L. Han, B. I. Hang, F. Bai, X. H. Pei, V. Nose, O. Burlingame, A. J. Capobianco, D. Orton, E. Lee, et al. Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis. PLoS One. 2014; 9: e101969.
18. H. Esumi, J. Lu, Y. Kurashima and T. Hanaoka. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methylqu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci. 2004; 95: 685-90.
19. T. C. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70: 440-6.
20. F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, M. L. Wen, R. Kramer, A. Blackwood-Chirchir, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006; 12: 7180-6.
21. S. Takeishi and K. I. Nakayama. Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Br J Cancer. 2014; 111:1054-9.
22. C. H. Jamieson, L. E. Ailles, S. J. Dylla, M. Muijtjens, C. Jones, J. L. Zehnder, J. Gotlib, K. Li, M. G. Manz, A. Keating, C. L. Sawyers and I. L. Weissman. Granulocytemacrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351: 657-67.
23. N. S. Chandel and P. T. Schumacker. Cells depleted of mitochondrial DNA (rho0) yield insight into physiological mechanisms. FEBS Lett. 1999; 454: 173-6.
24. J. C. Chomel and A. G. Turhan. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011; 2: 713-27.
25. M. G. Vander Heiden. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011; 10: 671-84.
26. G. J. Cook and T. S. Pardee. Animal models of leukemia: any closer to the real thing? Cancer and Metastasis Reviews. 2013; 32: 63-76.
27. A. Venerando, C. Girardi, M. Ruzzene and L. A. Pinna. Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. Biochem J. 2013; 452:131-7.
28. J. M. Funes, M. Quintero, S. Henderson, D. Martinez, U. Qureshi, C. Westwood, M. O. Clements, D. Bourboulia, R. B. Pedley, S. Moncada and C. Boshoff. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A. 2007; 104: 6223-8.
29. R. Moreno-Sanchez, S. Rodriguez-Enriquez, A. MarinHernandez and E. Saavedra. Energy metabolism in tumor cells. FEBS J. 2007; 274: 1393-418.
30. S. Chu, M. Holtz, M. Gupta and R. Bhatia. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood. 2004; 103: 3167-74.
31. K. Hashiguchi and Q. M. Zhang-Akiyama. Establishment of human cell lines lacking mitochondrial DNA. Methods Mol Biol. 2009; 554: 383-91.
32. J. K. Cheong, T. H. Nguyen, H. Wang, P. Tan, P. M. Voorhoeve, S. H. Lee and D. M. Virshup. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/varepsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation. Oncogene. 2011; 30: 2558-69.
33. S. Varum, A. S. Rodrigues, M. B. Moura, O. Momcilovic, C. A. t. Easley, J. Ramalho-Santos, B. Van Houten and G. Schatten. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One. 2011; 6: e20914.